Summary Cirrhosis and other chronic liver diseases due to other causes resulted in 8·44 million (95% UI 6·94–10·2) global DALYs in 2019.

Definition This cause includes cirrhosis and other chronic liver diseases due to causes other than hepatitis B, hepatitis C, alcohol, and NAFLD.

Total sources
Incidence 0
Prevalence 0
Remission 0
Causes of death 3828
Other 31
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •Meta-analysis was conducted in MR-BRT of five cirrhosis case-series studies that reported proportions due to both NASH and cryptogenic aetiologies; estimated ratio was used to adjust data that reported the proportion of cases due to cryptogenic but not NASH, under the assumption that these studies counted NASH cases in the cryptogenic category.
  • •Bias adjustment for claims data to hospital data in the USA was estimated using MR-BRT and applied to data, lowering claims data values differentially prior to analysis in DisMod-MR 2.1.
  • •Excess mortality data (EMR) were modelled in MR-BRT by age and sex as a function of the HAQ Index to provide greater guidance to DisMod-MR on expected pattern of EMR.
  • •We added mild, moderate, and severe anaemia health states to decompensated cirrhosis based on a review of the mean haemoglobin shift of 18 g/L in people with cirrhosis.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
11·4
(9·28
to 13·9)
144·7
(118·5
to 175·6)
0·522
(0·407
to 0·655)
6·9
(5·4
to 8·6)
0·240
(0·188
to 0·303)
3·0
(2·4
to 3·8)
8·25
(6·75
to 10·1)
104·9
(86·2
to 127·1)
0·187
(0·119
to 0·278)
2·5
(1·6
to 3·7)
8·44
(6·94
to 10·2)
107·3
(88·8
to 129·6)
Females
6·40
(5·19
to 7·85)
160·2
(130·8
to 195·9)
0·266
(0·209
to 0·328)
7·1
(5·6
to 8·7)
0·123
(0·0945
to 0·155)
2·9
(2·3
to 3·6)
3·89
(3·12
to 4·70)
97·5
(79·1
to 117·2)
0·0970
(0·0615
to 0·144)
2·6
(1·6
to 3·8)
3·99
(3·22
to 4·80)
100·0
(81·8
to 119·9)
Males
5·01
(4·03
to 6·13)
128·1
(104·4
to 156·2)
0·256
(0·197
to 0·328)
6·7
(5·2
to 8·5)
0·117
(0·0921
to 0·151)
3·1
(2·4
to 4·0)
4·36
(3·52
to 5·42)
111·9
(91·0
to 137·8)
0·0904
(0·0575
to 0·134)
2·4
(1·5
to 3·5)
4·45
(3·61
to 5·49)
114·3
(93·2
to 140·0)
Percentage change 2010-19
Both Sexes
21·1%
(17·4
to 24·6)
5·9%
(3·4
to 8·4)
13·9%
(9·8
to 18·1)
5·7%
(2·3
to 8·8)
11·0%
(4·3
to 17·7)
–9·0%
(–14·1
to –3·8)
1·6%
(–6·3
to 11·0)
–11·3%
(–18·3
to –3·5)
14·4%
(10·3
to 18·5)
3·6%
(–0·1
to 7·6)
1·8%
(–5·8
to 11·1)
–11·0%
(–17·9
to –3·3)
Females
22·2%
(18·3
to 25·9)
5·9%
(3·3
to 8·6)
15·4%
(10·9
to 19·9)
5·8%
(2·3
to 9·1)
11·7%
(4·1
to 19·5)
–9·2%
(–15·2
to –3·0)
1·1%
(–7·3
to 11·1)
–12·4%
(–20·0
to –3·2)
14·6%
(10·1
to 19·0)
3·2%
(–1·1
to 7·7)
1·4%
(–6·9
to 11·3)
–12·1%
(–19·5
to –3·0)
Males
19·8%
(15·9
to 23·4)
6·0%
(3·3
to 8·5)
12·5%
(8·5
to 16·3)
5·4%
(2·0
to 8·8)
10·2%
(2·0
to 19·0)
–8·7%
(–15·0
to –1·5)
2·0%
(–7·4
to 12·5)
–10·4%
(–18·1
to –1·1)
14·2%
(9·1
to 19·5)
4·1%
(–0·3
to 9·1)
2·2%
(–6·9
to 12·5)
–10·2%
(–17·7
to –1·0)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 49th 53rd 183rd 69th
2010 50th 47th 192nd 67th
2019 43rd 46th 190th 72nd
Table 3: Rank among most detailed causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by YLLs and constituent sequelae YLDs for both sexes combined, 2019
No Legend
Figure 2: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 3: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 4: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019